Skip to main content
Premium Trial:

Request an Annual Quote

Fisher Added to BCW Index

This week, Fisher Scientific becomes the latest company to join the BCW Index. The firm, which completed its purchase of high-content screening firm Cellomics a couple of weeks ago, has been a competitor to several firms in the Index over the past couple of years through its RNAi and protein assay kits and reagents, and now will compete against others with its cell screening operations (see related article).

For the five-day trading period ended Tuesday, Invitrogen led decliners with a drop of 8.35 percent. Its closing per share price of $76.91 is its lowest trading price since mid-June. Harvard Bioscience closed the week down 5.37 percent at $2.82, its lowest closing price over the past year.

Thermo Electron gained 8.16 percent during the tracking period. On Monday, investment bank Thomas Weisel upgraded the firm's shares to Outperform from Peer Perform. It was the third upgrade of the firm's shares since June, following similar actions by Robert W. Baird and JP Morgan.

Overall, the Index fell 1.36 percent. In comparison, the Dow Jones Industrial Average had a .1 percent gain, the Nasdaq rose .7 percent, and the Nasdaq Biotech Index closed up .7 percent.

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(September 13, 2005)
Last Price
(September 6, 2005)
% Change
Agilent
A
33.09
32.48
1.88
Applied Biosystems
ABI
23.13
21.76
6.30
Beckman
BEC
57.58
57.14
0.77
Bio-Rad
BIO
54.48
57.35
-5.00
Bruker
BRKR
4.56
4.41
3.40
Fisher Scientific
FSH
63.49
64.74
-1.93
GE
GE
34.28
33.94
1.00
Harvard Bio
HBIO
2.82
2.98
-5.37
Invitrogen
IVGN
76.91
83.92
-8.35
Molecular Devices
MDCC
20.63
21.07
-2.09
PerkinElmer
PKI
20.39
20.75
-1.73
Qiagen
QGEN
13.1
13.13
-0.23
Sigma
SIAL
62.51
61.85
1.07
Stratagene
STGN
6.96
7.41
-6.07
Thermo
TMO
30.76
28.44
8.16
Waters
WAT
45.2
46.1
-1.95
Index Average
34.37
34.84
-1.36
The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.